These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22724220)

  • 21. The ezetimibe controversy: implications for clinical practice.
    Khanderia U; Regal RE; Rubenfire M; Boyden T
    Ther Adv Cardiovasc Dis; 2011 Aug; 5(4):199-208. PubMed ID: 21636623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical trial subgroups: challenges and opportunities in describing the benefits of therapy.
    Spertus J
    Circ Cardiovasc Qual Outcomes; 2011 May; 4(3):266-7. PubMed ID: 21586724
    [No Abstract]   [Full Text] [Related]  

  • 23. Statin, the black box.
    Hatem S; Boccara F
    Arch Cardiovasc Dis; 2008 Jun; 101(6):377-9. PubMed ID: 18809149
    [No Abstract]   [Full Text] [Related]  

  • 24. Time course of atherosclerosis regression.
    Spence JD
    Atherosclerosis; 2014 Aug; 235(2):347-8. PubMed ID: 24911639
    [No Abstract]   [Full Text] [Related]  

  • 25. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design.
    Califf RM; Lokhnygina Y; Cannon CP; Stepanavage ME; McCabe CH; Musliner TA; Pasternak RC; Blazing MA; Giugliano RP; Harrington RA; Braunwald E
    Am Heart J; 2010 May; 159(5):705-9. PubMed ID: 20435175
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of previous statin use on the incidence of sustained ventricular tachycardia and ventricular fibrillation in patients presenting with acute coronary syndrome.
    Ozaydın M; Türker Y; Erdoğan D; Karabacak M; Varol E; Doğan A; Küçüktepe Z; Içli A
    Anadolu Kardiyol Derg; 2011 Feb; 11(1):22-8. PubMed ID: 21183417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Immediate Effects of Statins on Coronary Atherosclerosis: Can Phenotype Explain Outcome?
    Min JK; Chandrashekhar Y; Narula J
    JACC Cardiovasc Imaging; 2018 Jun; 11(6):839-841. PubMed ID: 28917681
    [No Abstract]   [Full Text] [Related]  

  • 28. [Statins in the management of acute coronary syndrome].
    Matoba T; Egashira K
    Nihon Rinsho; 2010 Apr; 68(4):692-8. PubMed ID: 20387563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Early administrations of statins after acute coronary syndrome].
    Linde JJ; Jensen GB
    Ugeskr Laeger; 2012 Jun; 174(26):1801-3. PubMed ID: 22735112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of statins on high-risk atherosclerotic plaque associated with low endothelial shear stress.
    Takahashi S; Papafaklis MI; Sakamoto S; Antoniadis AP; Coskun AU; Feldman CL; Stone PH
    Curr Opin Lipidol; 2011 Oct; 22(5):358-64. PubMed ID: 21841484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design.
    Lablanche JM; Danchin N; Farnier M; Tedgui A; Vicaut E; Alonso J; Crean P; Leone A; Morais J; Santini M; Licour M; Farah M; Tardif JC
    Arch Cardiovasc Dis; 2008 Jun; 101(6):399-406. PubMed ID: 18809153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability.
    Erbel C; Dengler TJ; Wangler S; Lasitschka F; Bea F; Wambsganss N; Hakimi M; Böckler D; Katus HA; Gleissner CA
    Basic Res Cardiol; 2011 Jan; 106(1):125-34. PubMed ID: 21116822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistence of combination of evidence-based medical therapy in patients with acute coronary syndromes.
    Amar J; Ferrières J; Cambou JP; Amelineau E; Danchin N
    Arch Cardiovasc Dis; 2008 May; 101(5):301-6. PubMed ID: 18656088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Vulnerable plaque burden post pharmacological and interventional treatments in patients with acute coronary syndrome and borderline lesion: intravascular ultrasound follow up results].
    Yu DQ; Lin SG; Zhou YL; Li G; Tan N; Dong HJ; Chen JY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Feb; 39(2):137-41. PubMed ID: 21426748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From prevention to plaque rupture and infarction.
    Lüscher TF
    Eur Heart J; 2015 May; 36(17):1003-4. PubMed ID: 25934672
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG).
    Javed U; Deedwania PC; Bhatt DL; Cannon CP; Dai D; Hernandez AF; Peterson ED; Fonarow GC
    Am Heart J; 2010 Dec; 160(6):1130-6, 1136.e1-3. PubMed ID: 21146668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostaglandin E1 dose-dependently promotes stability of atherosclerotic plaque in a rabbit model.
    Bai W; Zheng X; Zhou L; Li H
    Can J Physiol Pharmacol; 2012 Feb; 90(2):131-9. PubMed ID: 22309388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation.
    Abela GS
    J Clin Lipidol; 2010; 4(3):156-64. PubMed ID: 21122648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statin therapy and the management of acute coronary syndromes.
    Langer A; Constance C; Fodor JG; Frohlich JJ; Grégoire J; Lau DC; Leiter LA; Mancini GB; Marr D; McPherson R; O'Neill BJ; Rabkin SW
    Can J Cardiol; 2003 Jul; 19(8):921-7. PubMed ID: 12876613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review.
    Mihos CG; Salas MJ; Santana O
    Cardiol Rev; 2010; 18(6):298-304. PubMed ID: 20926939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.